ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IAM / forecast
AURA (29) CADL (33) FDMT (44) SLDB (26) ⌘ Pro Terminal →

Iambic Therapeutics Inc. (IAM) 12-Month Stock Forecast & Price Target Cone

$13.43 -5.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.26

Iambic Therapeutics Inc. (IAM) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $636.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IAM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IAM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Iambic Therapeutics Inc. (NASDAQ: IAM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $13.43 (-5.95% 1D, market cap $636.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IAM ranks #305 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IAM compare to AURA and CADL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IAM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, IAM leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IAM?
▼

For Iambic Therapeutics Inc. (IAM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #305 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.26 (-1.26%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
$26 Bull$13 Base$10 Bear
📬 FREE IAM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IAM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY IAM SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($17.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$23.81-38.4% Next Q
Q2 (-2Q)
52
Grade C-$14.67+0.7% Next Q
Q3 (-1Q)
50
Grade C-$14.78-9.1% Next Q
Current
47
Grade D$13.43-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IAM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IAM currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.64) and Max Pain ($14.10) forces dealer call-delta covering toward $26.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IAM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IAM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IAM Position Size: $10,000

Shares at $13.43: 744.6 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $9.96
$7,416
$-2,584 (-25.8%)
12M Consensus BaseTarget $12.77
$9,509
$-491 (-4.9%)
12M Bull Case BreakoutTarget $26.25
$19,546
+$9,546 (+95.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1374%A
Goldman SachsSector Coverage LeadUNDERPERFORM$2569%B
JP MorganUS Large-Cap ResearchSELL$1158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IAM)

  • ✓Walkthrough of IAM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IAM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.98%
2026-11-02O $13.43H $13.55L $12.02C $13.43VOL 402.7K
SMA50: $15.70
$25.91$22.14$18.38$14.62$10.85$13.432026-10-152026-10-202026-10-232026-10-282026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IAM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IAM Butterfly Map → + Track IAM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IAM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IAM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IAM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IAM)

Health Care Rank #305 of 1015 ⚔️ AURA vs IAM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IAM vs. AURA, CADL, FDMT, SLDB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Iambic Therapeutics Inc. (IAM) ranks #305 by composite RQD confidence (47/100, grade D) and #407 by equity capitalization ($636.6M). Within this direct 5-issuer industry benchmark cohort, IAM leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IAM ACTIVE
Iambic Therapeutics Inc.
D 47/100 — — — -5.95% $636.6M Benchmark Subject
AURA
Aura Biosciences Inc.
E 29/100 — — -35.0% -2.46% $636.7M /aura-vs-iam →
CADL
Candel Therapeutics Inc.
E 33/100 — — -35.0% -3.70% $637.4M /cadl-vs-iam →
FDMT
4D Molecular Therapeutics Inc.
D 44/100 — — -28.3% -6.89% $657.4M /fdmt-vs-iam →
SLDB
Solid Biosciences Inc.
E 26/100 — — -35.0% -2.97% $664.8M /sldb-vs-iam →

2. IAM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Iambic Therapeutics Inc. (IAM) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $636.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IAM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IAM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Iambic Therapeutics Inc. (NASDAQ: IAM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $13.43 (-5.95% 1D, market cap $636.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IAM ranks #305 in composite RQD confidence.

How does IAM compare to AURA and CADL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IAM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, IAM leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IAM?

For Iambic Therapeutics Inc. (IAM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #305 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IAM trading relative to its 50-day, 200-day, and 52-week technical levels?

IAM last traded at $13.43 (-5.95% on volume of 476,897 shares), positioning the stock -8.27% below its 50-day simple moving average ($14.64) and -8.33% below its 200-day simple moving average ($14.65). Across its 52-week range of $12.02 to $25.00, IAM sits at the 10.9% percentile with a 14-day RSI of 38.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.75 to $15.11).

Direct Sub-Reports: IAM RQD Cockpit IAM 12M Forecast IAM Earnings & Move IAM Dividends & DRIP IAM Insiders & 13F IAM Whale Options IAM Profit Sankey IAM News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

IAM — Iambic Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Iambic Therapeutics Inc. (IAM) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $13.43 (-5.95% 1D, market capitalization $636.6M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Iambic Therapeutics Inc. (IAM) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances)..7B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $12.02 – $25.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links are mapped, and no sector correlations or proprietary signals are provided. Investors should note that the sector and industry classification alone is not sufficient to identify 2nd-order bottlenecks.

  • Key Question #1: Can IAM sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $25.00 52-week high?
  • Key Question #3: How sensitive is IAM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IAM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Iambic Therapeutics Inc. (IAM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IAM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IAM Bull vs. Bear Conversation Board — What's Your Call at $13.43?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IAM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IAM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $15.81 (+22.0%)
📌 Pinned Debate

The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest part of the rating.

Picked up a starter position in IAM in my $100K Virtual Cash book at $12.96. The forensic balance sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest part of the rating.. Trading inside a $12.06–$25.00 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $10.50 (-19.0%)
Spot @ $12.96

ROIC and FCF yield are both 0% and the whale/13F flow pillar scores only 5/20, leaving no reported earnings or institutional support an

Careful chasing IAM at $12.96. ROIC and FCF yield are both 0% and the whale/13F flow pillar scores only 5/20, leaving no reported earnings or institutional support anchoring the price.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $10.50 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%